CASI Pharmaceuticals
We have no price for CASI Pharmaceuticals since 13 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
CASI Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| CASI Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads CASI Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -0.67 | -0.40 | −67.5% |
| Aug 29, 2025 | -0.86 | -0.47 | −83.0% |
| May 16, 2025 | -0.69 | -0.61 | −13.1% |
| Mar 31, 2025 | -0.79 | -0.60 | −31.7% |
| Nov 15, 2024 | -0.55 | -0.62 | +11.3% |
| Aug 16, 2024 | -0.52 | -0.63 | +17.5% |
| May 14, 2024 | -0.71 | -0.05 | −1,320.0% |
| Mar 28, 2024 | -0.29 | -0.24 | −20.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about CASI Pharmaceuticals
Is CASI Pharmaceuticals a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CASI Pharmaceuticals AI analysis
What does CASI Pharmaceuticals do?
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. It is in Biotechnology.
Who are CASI Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with CASI Pharmaceuticals's.
Prices: daily closes to Apr 13, 2026. Fundamentals: company reports via invest-like data.